Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.

ABSTRACT:

Background

Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Previously, dexamethasone demonstrated a reduction of case-fatality rate in hospitalized patients with respiratory failure. In this matched control study we compared dexamethasone to a Janus kinase inhibitor, ruxolitinib.

Methods

The matched cohort study included 146 hospitalized patients with COVID-19 and oxygen support requirement. The control group was selected 1:1 from 1355 dexamethasone-treated patients and was matched by main clinical and laboratory parameters predicting survival. Recruitment period was April 7, 2020 through September 9, 2020.

Results

Ruxolitinib treatment in the gener

SUBMITTER: Stanevich OV 

PROVIDER: S-EPMC8693127 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature